
Mounjaro and Wegovy reimbursement applications in Poland remain under negotiation
WA SourceWarszawa w PigułceWarsaw

Poland’s AOTMiT agency issued negative recommendations on proposed public funding for the obesity drugs Mounjaro and Wegovy on June 29 and September 28, 2026, respectively. Those opinions did not, however, end the reimbursement process.
On October 29, the Economic Commission sent applications for various Wegovy doses back for renewed negotiations. The drug was also placed on the commission’s work schedule for November 9–10. This means discussions continue, but does not by itself introduce a discounted pharmacy price.
As of November 13, no final reimbursement decision had been announced for Mounjaro or Wegovy in obesity treatment. The health minister makes that decision; potential patient criteria and funding terms have not yet been established.
Loading…